Smith J T, Gavey C, Nwokolo C U, Pounder R E
Academic Department of Medicine, Royal Free Hospital School of Medicine, London, UK.
Aliment Pharmacol Ther. 1990;4 Suppl 1:47-63.
Simultaneous 24-h intragastric and plasma gastrin concentrations were measured in 36 healthy subjects, when receiving placebo (day 0) and on days 1 and 8 of dosing with either placebo (n = 8), or high-dose H2-blockade with either ranitidine 300 mg q.d.s. (n = 8), ranitidine 1200 mg o.m. (n = 8), or sufotidine 600 mg b.d. (n = 12). Triplicate placebo studies demonstrated good reproducibility for this technique, with no significant differences of acidity or plasma gastrin concentration between the studies. There was a decrease in the anti-secretory activity of all three high-dose H2-antagonist regimens on day 8, when compared with that observed on day 1. This occurred in the presence of sustained or increasing hypergastrinaemia. It is concluded that a degree of tolerance develops during continued H2-blockade, and that this could be due to increasing gastrin drive to the parietal cells.
在36名健康受试者中测量了同时进行的24小时胃内和血浆胃泌素浓度,这些受试者在接受安慰剂时(第0天)以及在使用安慰剂(n = 8)或高剂量H2受体阻滞剂(雷尼替丁300 mg,每日四次,n = 8;雷尼替丁1200 mg,每晚一次,n = 8;或法莫替丁600 mg,每日两次,n = 12)给药的第1天和第8天。三次重复的安慰剂研究表明该技术具有良好的可重复性,各研究之间的酸度或血浆胃泌素浓度无显著差异。与第1天观察到的情况相比,所有三种高剂量H2拮抗剂方案在第8天的抗分泌活性均有所下降。这发生在持续或不断增加的高胃泌素血症的情况下。结论是在持续的H2受体阻滞过程中会产生一定程度的耐受性,这可能是由于胃泌素对壁细胞的驱动增加所致。